Tepid 4Q for Indian firms amid ANDA trickle, currency woes?
This article was originally published in Scrip
Fourth quarter earnings seasons in India may by and large be a lukewarm affair, with a slowdown in the number of ANDA approvals, currency headwinds and continuing FDA scrutiny at domestic sites expected to rein in growth across a clutch of Indian firms.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.